[1]
Fraser CL, Hepschke JL, Jenkins B, Prasad S. Migraine Aura: Pathophysiology, Mimics, and Treatment Options. Seminars in neurology. 2019 Dec:39(6):739-748. doi: 10.1055/s-0039-1700525. Epub 2019 Dec 17
[PubMed PMID: 31847045]
[2]
. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018 Jan:38(1):1-211. doi: 10.1177/0333102417738202. Epub
[PubMed PMID: 29368949]
[3]
Merikangas KR, Risch NJ, Merikangas JR, Weissman MM, Kidd KK. Migraine and depression: association and familial transmission. Journal of psychiatric research. 1988:22(2):119-29
[PubMed PMID: 3404480]
[4]
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia : an international journal of headache. 2007 May:27(5):394-402
[PubMed PMID: 17403039]
[5]
Marmura MJ. Triggers, Protectors, and Predictors in Episodic Migraine. Current pain and headache reports. 2018 Oct 5:22(12):81. doi: 10.1007/s11916-018-0734-0. Epub 2018 Oct 5
[PubMed PMID: 30291562]
[6]
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet. Neurology. 2017 Jan:16(1):76-87. doi: 10.1016/S1474-4422(16)30293-9. Epub 2016 Nov 9
[PubMed PMID: 27836433]
[7]
Jen JC, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Archives of neurology. 2004 Jun:61(6):926-8
[PubMed PMID: 15210532]
[8]
Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain : a journal of neurology. 2015 Dec:138(Pt 12):3476-95. doi: 10.1093/brain/awv317. Epub 2015 Nov 23
[PubMed PMID: 26598493]
[9]
Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May:59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14
[PubMed PMID: 30982963]
[10]
Deen M, Christensen CE, Hougaard A, Hansen HD, Knudsen GM, Ashina M. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia : an international journal of headache. 2017 Mar:37(3):251-264. doi: 10.1177/0333102416640501. Epub 2016 Jul 11
[PubMed PMID: 27013238]
Level 1 (high-level) evidence
[11]
Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, Legius E, Riant F, De Jonghe P, Li Y, Sekine T, Igarashi T, Fujimoto I, Mikoshiba K, Shimadzu M, Shiohara M, Braverman N, Al-Gazali L, Fujita T, Seki G. Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proceedings of the National Academy of Sciences of the United States of America. 2010 Sep 7:107(36):15963-8. doi: 10.1073/pnas.1008705107. Epub 2010 Aug 23
[PubMed PMID: 20798035]
[12]
Lee HN, Eom S, Kim SH, Kang HC, Lee JS, Kim HD, Lee YM. Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). Pediatric neurology. 2016 Nov:64():59-65. doi: 10.1016/j.pediatrneurol.2016.08.016. Epub 2016 Aug 26
[PubMed PMID: 27671241]
Level 2 (mid-level) evidence
[13]
Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A, European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain. 2017 Sep 25:18(1):96. doi: 10.1186/s10194-017-0807-1. Epub 2017 Sep 25
[PubMed PMID: 28948500]
[14]
Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2017 Dec:31(6):487-501. doi: 10.1007/s40259-017-0250-5. Epub
[PubMed PMID: 29116598]
[15]
Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet (London, England). 2019 Nov 9:394(10210):1765-1774. doi: 10.1016/S0140-6736(19)32504-8. Epub 2019 Oct 23
[PubMed PMID: 31668411]
[16]
Gasparini CF, Smith RA, Griffiths LR. Genetic and biochemical changes of the serotonergic system in migraine pathobiology. The journal of headache and pain. 2017 Dec:18(1):20. doi: 10.1186/s10194-016-0711-0. Epub 2017 Feb 13
[PubMed PMID: 28194570]
[17]
Sutherland HG, Griffiths LR. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders. Headache. 2017 Apr:57(4):537-569. doi: 10.1111/head.13053. Epub 2017 Mar 8
[PubMed PMID: 28271496]
[18]
Viana M, Tronvik EA, Do TP, Zecca C, Hougaard A. Clinical features of visual migraine aura: a systematic review. The journal of headache and pain. 2019 May 30:20(1):64. doi: 10.1186/s10194-019-1008-x. Epub 2019 May 30
[PubMed PMID: 31146673]
Level 1 (high-level) evidence
[19]
Evans RW, Burch RC, Frishberg BM, Marmura MJ, Mechtler LL, Silberstein SD, Turner DP. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache. 2020 Feb:60(2):318-336. doi: 10.1111/head.13720. Epub 2019 Dec 31
[PubMed PMID: 31891197]
Level 1 (high-level) evidence
[20]
Hsu YC, Lin KC, Taiwan Headache Society TGSOTHS. Medical Treatment Guidelines for Acute Migraine Attacks. Acta neurologica Taiwanica. 2017 Jun 15:26(2):78-96
[PubMed PMID: 29250761]
[21]
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug:55 Suppl 4():221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14
[PubMed PMID: 26178694]
Level 1 (high-level) evidence
[22]
Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun:55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15
[PubMed PMID: 25877672]
[23]
Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. The American journal of medicine. 2020 Apr:133(4):412-416. doi: 10.1016/j.amjmed.2019.10.023. Epub 2019 Nov 9
[PubMed PMID: 31712099]
[24]
Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4:297(13):1443-54
[PubMed PMID: 17405970]
Level 1 (high-level) evidence
[25]
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. The New England journal of medicine. 2019 Dec 5:381(23):2230-2241. doi: 10.1056/NEJMoa1813049. Epub
[PubMed PMID: 31800988]
[26]
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11:91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16
[PubMed PMID: 30446595]
Level 1 (high-level) evidence
[27]
Giamberardino MA, Affaitati G, Costantini R, Guglielmetti M, Martelletti P. Acute headache management in emergency department. A narrative review. Internal and emergency medicine. 2020 Jan:15(1):109-117. doi: 10.1007/s11739-019-02266-2. Epub 2020 Jan 1
[PubMed PMID: 31893348]
Level 3 (low-level) evidence
[28]
Mirbaha S, Delavar-Kasmaei H, Erfan E. Effectiveness of the Concurrent Intravenous Injection of Dexamethasone and Metoclopramide for Pain Management in Patients with Primary Headaches Presenting to Emergency Department. Advanced journal of emergency medicine. 2017 Fall:1(1):e6. doi: 10.22114/AJEM.v1i1.12. Epub 2017 Oct 12
[PubMed PMID: 31172058]
[29]
Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia : an international journal of headache. 2019 Jan:39(1):3-14. doi: 10.1177/0333102418811573. Epub 2018 Nov 17
[PubMed PMID: 30449151]
Level 1 (high-level) evidence
[30]
Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. The journal of headache and pain. 2015:16():535. doi: 10.1186/s10194-015-0535-3. Epub 2015 Jun 3
[PubMed PMID: 26055242]
Level 3 (low-level) evidence
[31]
Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia : an international journal of headache. 2018 May:38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4
[PubMed PMID: 29504483]
Level 2 (mid-level) evidence
[32]
Rapoport AM, Bonner JH, Lin T, Harris D, Gruper Y, Ironi A, Cowan RP. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. The journal of headache and pain. 2019 Jul 22:20(1):83. doi: 10.1186/s10194-019-1033-9. Epub 2019 Jul 22
[PubMed PMID: 31331265]
[33]
Korucu O, Dagar S, Çorbacioglu ŞK, Emektar E, Cevik Y. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta neurologica Scandinavica. 2018 Sep:138(3):212-218. doi: 10.1111/ane.12952. Epub 2018 May 10
[PubMed PMID: 29744871]
[34]
Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache. 2019 Sep:59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25
[PubMed PMID: 31342515]
Level 3 (low-level) evidence
[35]
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24:78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Epub
[PubMed PMID: 22529202]
Level 2 (mid-level) evidence
[36]
Kahriman A, Zhu S. Migraine and Tension-Type Headache. Seminars in neurology. 2018 Dec:38(6):608-618. doi: 10.1055/s-0038-1673683. Epub 2018 Dec 6
[PubMed PMID: 30522135]
[37]
Holle-Lee D, Nägel S, Gaul C. [Therapy of migranes]. Der Nervenarzt. 2017 Aug:88(8):929-941. doi: 10.1007/s00115-017-0338-7. Epub
[PubMed PMID: 28497257]
[38]
Ruscheweyh R, Förderreuther S, Gaul C, Gendolla A, Holle-Lee D, Jürgens T, Neeb L, Straube A. [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society]. Der Nervenarzt. 2018 Dec:89(12):1355-1364. doi: 10.1007/s00115-018-0534-0. Epub
[PubMed PMID: 29947936]
[39]
Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. Pharmaceutics. 2022 Jun 1:14(6):. doi: 10.3390/pharmaceutics14061190. Epub 2022 Jun 1
[PubMed PMID: 35745763]
Level 1 (high-level) evidence
[40]
Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan:60(1):58-70. doi: 10.1111/head.13663. Epub 2019 Oct 24
[PubMed PMID: 31647577]
Level 1 (high-level) evidence
[41]
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan:55(1):3-20. doi: 10.1111/head.12499. Epub
[PubMed PMID: 25600718]
[42]
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane database of systematic reviews. 2014 May 28:2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2. Epub 2014 May 28
[PubMed PMID: 24865446]
Level 3 (low-level) evidence
[43]
Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The journal of headache and pain. 2017 Dec:18(1):17. doi: 10.1186/s10194-016-0717-7. Epub 2017 Feb 7
[PubMed PMID: 28176235]
Level 1 (high-level) evidence
[44]
Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clinical therapeutics. 2000 Aug:22(8):970-80
[PubMed PMID: 10972633]
[45]
Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. The Cochrane database of systematic reviews. 2014 May 21:2014(5):CD008616. doi: 10.1002/14651858.CD008616.pub2. Epub 2014 May 21
[PubMed PMID: 24848613]
Level 1 (high-level) evidence
[46]
Oldman AD, Smith LA, McQuay HJ, Moore AR. Pharmacological treatments for acute migraine: quantitative systematic review. Pain. 2002 Jun:97(3):247-257. doi: 10.1016/S0304-3959(02)00024-6. Epub
[PubMed PMID: 12044621]
Level 1 (high-level) evidence
[47]
. Eletriptan (relpax) for migraine. The Medical letter on drugs and therapeutics. 2003 Apr 28:45(1155):33-4
[PubMed PMID: 12719695]
Level 3 (low-level) evidence
[48]
Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb:52(2):292-306. doi: 10.1111/j.1526-4610.2011.02070.x. Epub
[PubMed PMID: 22309235]
[49]
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. The New England journal of medicine. 2019 Jul 11:381(2):142-149. doi: 10.1056/NEJMoa1811090. Epub
[PubMed PMID: 31291516]
[50]
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15:325(23):2357-2369. doi: 10.1001/jama.2021.7939. Epub
[PubMed PMID: 34128998]
Level 1 (high-level) evidence
[51]
Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clinic proceedings. 1996 Nov:71(11):1055-66
[PubMed PMID: 8917290]
Level 3 (low-level) evidence
[52]
Ikeda K, Aoyagi J, Hanashiro S, Sawada M, Kyuzen M, Morioka H, Ebina J, Nagasawa J, Yanagihashi M, Ishikawa Y, Miura K, Murata K, Takazawa T, Kawabe K, Iwasaki Y. Preventive Treatment with Lomerizine Increases Cerebral Blood Flows during the Interictal Phase of Migraine. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2018 Apr:27(4):998-1002. doi: 10.1016/j.jstrokecerebrovasdis.2017.11.004. Epub 2017 Dec 6
[PubMed PMID: 29221971]
[53]
Ashina M, Goadsby PJ, Dodick DW, Tepper SJ, Xue F, Zhang F, Brennan F, Paiva da Silva Lima G. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA neurology. 2022 Feb 1:79(2):159-168. doi: 10.1001/jamaneurol.2021.4678. Epub
[PubMed PMID: 34928306]
Level 1 (high-level) evidence